Coverage
-
March 20, 2014
KV Pharmaceutical Co. and the lead plaintiffs in a securities class action alleging the drugmaker hid U.S. Food and Drug Administration violations to inflate its share price have reached a $12.8 million settlement agreement that, if approved, would end more than five years of litigation, according to a filing in Missouri federal court Wednesday.
1 other articles on this case.
View all »